Loading resource…

Universitätsklinikum der Technischen Universität München, Germany
Dyslipidaemia, particularly elevated low-density lipoprotein cholesterol (LDL-C), is a significant modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). The paper addresses the underdiagnosis and undertreatment of dyslipidaemia, especially in high-risk patients. It emphasizes the importance of lifestyle interventions and outlines treatment options including statins, ezetimibe, and novel therapies. The document incorporates the latest recommendations from the 2025 Focused Update of the ESC/EAS guidelines, highlighting the need for individualized treatment approaches.
No account needed